Biogen Inc. (BIIB) Financial Analysis

In short

Biogen Inc. (BIIB) has revenue up 2.2% to $9.9B and net income down 20.8% to $1.3B year on year. Its net margin is 13.1%, and it trades at 38.8× trailing earnings. Fisclear found no medium- or high-severity risk flags in this filing. How we calculate this

Valuation

Healthcare

Live · Yahoo Finance

Price

$253.96

Market Cap

$37.5B

P/E (TTM)

45.1x

Price ÷ earnings per share

P/B

2.0x

Price ÷ book value

P/S (TTM)

3.7x

Price ÷ revenue per share

EV / EBITDA

12.7x

Beta

0.09

Low volatility vs market

PEG Ratio

2.5x

P/E ÷ earnings growth rate

52-Week Range

$138.00$253.96 now$254.29

Decision Context

Market appears to be pricing in less growth than this company's historical average, suggesting potential upside if the trajectory continues. Quality and efficiency scores support the business case.

Based on filing period ending Jun 2026

FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.

BIIB vs

Macro Context

Fed Funds Rate

3.75%

Accommodative

10-Year Treasury

4.99%

2026-09-01

Unemployment

4.2%

Near full employment

CPI Index

334.1

2026-08-01

M2 Money Supply

$23.3T

2026-08-01

The Federal Funds rate stands at 3.75% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 4.99%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.2%; Industrial production index is at 103.1; M2 money supply is $23.3T; CPI index stands at 334.1.

SWOT Analysis — BIIB

Inflationary Boom

✦

Strengths

Total Assets: $29.4B (+5.0% YoY) — Total assets grew 5% — the company's resource base expanded.

◈

Weaknesses

Operating Cash Flow: $2.2B (-23.3% YoY) — Operating cash flow fell 23% but remained positive.
EPS (Diluted): $8.79 (-21.4% YoY) — Earnings per share fell 21%.
Net Income: $1.3B (-20.8% YoY) — Profit fell 21% but remained positive.

◎

Opportunities

Revenue: $9.9B (+2.2% YoY) — Revenue grew 2% — the company sold more goods or services than the prior year.

⚠

Threats

No significant threats flagged.

Quarter-over-Quarter Comparison

2026-03-31 → 2026-06-30

Metric	2026-03-31	2026-06-30	Change
Revenue	$9.9B	$9.9B	–0.0%
Gross Profit	$11.6B	0.00	▼100.0%
Operating Income	$2.8B	0.00	▼100.0%
Net Income	$1.3B	$1.3B	–0.0%
EPS (diluted)	$8.79	$8.79	–0.0%
Operating CF	$2.2B	$2.2B	–0.0%

Risk factor changes vs prior filing

REMOVED

Gross margin compressed by 10.7pp — input costs or pricing pressure is eroding profitability on each dollar of revenue.

Year-over-Year Changes

Operating Cash Flow

$2.2B

was $2.9B

−23.3%

Operating cash flow fell 23% but remained positive.

EPS (Diluted)

$8.79

was $11.18

−21.4%

Earnings per share fell 21%.

Net Income

$1.3B

was $1.6B

−20.8%

Profit fell 21% but remained positive.

Total Assets

$29.4B

was $28.0B

+5.0%

Total assets grew 5% — the company's resource base expanded.

Revenue

$9.9B

was $9.7B

+2.2%

Revenue grew 2% — the company sold more goods or services than the prior year.

Technical Signals

Daily closes · 1-year data

Biogen Inc.: common questions

Is Biogen Inc. profitable?

Yes. Biogen Inc. made a net profit of $1.3B in its latest fiscal year (fiscal 2025), a net margin of 13.1%.

Is Biogen Inc.'s revenue growing?

Yes. Revenue grew 2.2% year on year, to $9.9B.

What is Biogen Inc.'s P/E ratio?

Biogen Inc. trades at 45.1× its trailing twelve-month earnings. In other words, the share price is about 45 times the profit per share the company earned over the past year.